Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J, REGARD Trial Investigators

Open source

DOI: 10.1016/s0140-6736(13)61719-5
Published: 2014 Jan 4
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-13-61719-5,
  title = {Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.},
  author = {Fuchs CS and Tomasek J and Yong CJ and Dumitru F and Passalacqua R and Goswami C and Safran H and Dos Santos LV and Aprile G and Ferry DR and Melichar B and Tehfe M and Topuzov E and Zalcberg JR and Chau I and Campbell W and Sivanandan C and Pikiel J and Koshiji M and Hsu Y and Liepa AM and Gao L and Schwartz JD and Tabernero J and REGARD Trial Investigators},
  year = {2014},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(13)61719-5},
  url = {https://doi.org/10.1016/s0140-6736(13)61719-5}
}

RIS

TY  - JOUR
TI  - Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
AU  - Fuchs CS
AU  - Tomasek J
AU  - Yong CJ
AU  - Dumitru F
AU  - Passalacqua R
AU  - Goswami C
AU  - Safran H
AU  - Dos Santos LV
AU  - Aprile G
AU  - Ferry DR
AU  - Melichar B
AU  - Tehfe M
AU  - Topuzov E
AU  - Zalcberg JR
AU  - Chau I
AU  - Campbell W
AU  - Sivanandan C
AU  - Pikiel J
AU  - Koshiji M
AU  - Hsu Y
AU  - Liepa AM
AU  - Gao L
AU  - Schwartz JD
AU  - Tabernero J
AU  - REGARD Trial Investigators
PY  - 2014
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(13)61719-5
UR  - https://doi.org/10.1016/s0140-6736(13)61719-5
ER  -

APA

CS, F., J, T., CJ, Y., F, D., R, P., C, G., H, S., LV, D. S., G, A., DR, F., B, M., M, T., E, T., JR, Z., I, C., W, C., C, S., J, P., M, K., Y, H., AM, L., L, G., JD, S., J, T., & Investigators, R. T. (2014). Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(13)61719-5

Source records

pubmed · retrieved 2026-09-26T09:43:27.632Z